Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

Patricia M. LoRusso, Aleksandar Sekulic, Jeffrey A. Sosman, Winnie S. Liang, John Carpten, David W. Craig, David B. Solit, Alan H. Bryce, Jeffrey A. Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A. Byron, Mary Jo Pilat, Scott A. Boerner, Diane Durecki, William P.D. Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan KeatsChristophe Legendre, Svetomir N. Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D. Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S. Calvert, Emanuel F. Petricoin, Leslie Anne Fecher, Christopher Lao, J. Paul Eder, Nicholas J. Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W. Joseph, C. Lance Cowey, Jeffrey M. Trent*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial'. Together they form a unique fingerprint.

INIS

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology